Picture a living cell as if it were a city. If you were the urban planner for this (very little, very alive) city, one of the ...

The question of how life could have emerged is one of the most long-standing mysteries in science. In a new study, the ...

Macrophages play a central role in the development of atherosclerotic cardiovascular disease (ASCVD), which encompasses coronary artery disease, peripheral artery disease, cerebrovascular disease, and ...

ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with ...

Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer FGFR2b protein ...

Understanding the role of phagocytosis regulators in female-specific cancers is essential for developing effective therapeutic strategies. Methods: We performed comprehensive analyses of public ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval our partner Jazz Pharmaceuticals received from the U.S. Food and Drug Administration in 2024 for Ziihera® ...

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the ...

The company's phase 3 Essence study tested the therapy in patients with moderate hypertriglyceridemia who have or are at risk for atherosclerotic cardiovascular disease (ASCVD ...

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the ...

Edited* by Xiaodong Wang, University of Texas Southwestern Medical Center, Dallas, TX, and approved September 7, 2010 (received for review June 24, 2010) ...

But with promising early results from a phase 3 study in certain patients, the checkpoint inhibitor may have found its place. At a pre-specified interim analysis of Merck’s phase 3 Keynote-B96 ...